Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseases New York/London, 24 August, 2020 - Tizi

Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6

receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseases

New York/London, 24 August, 2020 - Tiziana Life Sciences

plc (Nasdaq: TLSA; AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative

therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office

("USPTO") has granted a patent for methods and use of fully human monoclonal antibody (mAb; TZLS-501) that recognizes

both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for

human diseases. The Company initially entered into a world-wide exclusive license from Novimmune, SA., a Swiss Biotechnology company

in 2017. The license is currently maintained with Bristol Myers Squibb. The patent (No. 10,759,862) will be published by the USPTO

on September 1, 2020. The grant of this additional patent on TZLS-501 is of particular significance for the potential treatment

of COVID-19 and other pulmonary diseases such as acute respiratory distress syndrome (ARDS).

The major distinguishing feature of TZLS-501 is that it acts

via a dual mechanism by not only inhibiting IL-6R signaling but also depleting circulating levels of IL-6. This distinctive feature

of TZLS-501, a fully human anti-IL-6R mAb, makes it potentially suitable for treatment of COVID-19 and ARDS. For example, COVID-19

patients often develop an uncontrolled immune response ("cytokine storm") resulting in severe damage to the lung tissue

which could lead to respiratory failure. Many studies have also indicated excessive levels of IL-6 in the lungs and in the blood

of these patients, and it is believed that the cytokine storm in lungs is primarily due to excessive levels of IL-6. Hence, direct

inhalation delivery of TZLS-501 to the lungs using a hand-held nebulizer has the potential to deplete circulating levels of IL-6

and inhibit IL-6R signaling thus providing immediate relief to COVID-19 patients.

"The granting of this patent along with our previously

filed patent application on inhalation delivery of anti-IL-6 mAbs strengthens our intellectual property for the treatment of lung

diseases. We are expediting the clinical development of TZLS-501, GMP manufacturing, simultaneously developing inhalation delivery

directly to the lungs using a nebulizer and conducting the inhalation safety toxicology studies in Cynomolgus monkeys. Completion

of these studies will enable us to file an IND and initiate a clinical trial in COVID-19 patients by Q1 2021. Subsequently, we

plan to use TZLS-501 with the same inhalation delivery technology for the treatment of patients with ARDS", added Dr. Kunwar

Shailubhai, CEO & CSO of Tiziana.

The person who arranged for the release of this announcement

on behalf of the Company was Dr Kunwar Shailubhai, CEO & CSO of Tiziana.

TZLS-501, a fully human mAb, was acquired from Novimmune, SA,

a Swiss biotechnology company, in 2017. The cytokine, IL-6, a major determinant in the priming of pathogenic T cells to produce

an inflammatory response, binds to its receptor subunit IL-6R on the cell membrane. The receptor IL-6R can be shed

in soluble form, sIL6R , which binds to circulating IL-6 cytokine in the blood. The downstream signaling from this complex

mediates pro-inflammatory effects underlying inflammatory diseases such as rheumatoid arthritis (RA) and acute respiratory distress

syndrome (ARDS). The Company believes that the features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling

by the membrane-bound and soluble IL-6 receptor and the rapid depletion of circulating IL-6 cytokines, a major cause of lung damage,

suggests a potential role for TZLS-501 in patient management and treatment of COVID-19.

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA &

UK AIM: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in

oncology, inflammation, and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies

with orally administered foralumab for Crohn's disease and nasally administered foralumab for progressive multiple sclerosis.

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase 2 compound

has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's disease, multiple sclerosis,

type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response

is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody

for treatment of IL6-induced inflammation, especially for treatment of hospitalized COVID-19 patients with severe respiratory symptoms.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking

statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations,

estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,'

'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements

are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of

which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those

expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders

not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this

announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements

are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements

to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law

or by any appropriate regulatory authority.

This announcement contains inside information for the purposes

of Article 7 of EU Regulation 596/2014.

For further enquiries: